The primary objective is to determine whether candesartan, compared to placebo reduces the
incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients
without retinopathy.
The secondary objective is to determine whether candesartan, compared to placebo,
beneficially influences the rate of change in urinary albumin excretion rate (UAER).
This study is part of the DIRECT Programme also including secondary prevention studies of
diabetic retinopathy in both type 1 and type 2 diabetes. The primary objective for all three
pooled studies is to determine whether candesartan, compared to placebo, reduces the
incidence of microalbuminuria in type 1 and type 2 diabetic patients.